Drug intelligence / Profile preview

I-DROP

Development stage
Unknown
Lead developer
I-MED Pharma
Modality
Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Ophthalmic
01

Overview

I-DROP is a family of viscoadaptive artificial tear solutions developed by I-MED Pharma for the management of dry eye disease and ocular surface irritation. The primary active ingredient across the product line is sodium hyaluronate, a high-molecular-weight glycosaminoglycan that provides superior lubrication and hydration to the cornea. The viscoadaptive technology allows the formulation to change its rheological properties in response to blinking: the solution thins during the blink to ensure clear vision and thickens between blinks to provide a long-lasting, protective coating. This dual action reduces the frequency of application compared to traditional artificial tears. The product range includes preservative-free formulations and specialized versions like I-DROP MGD, which incorporates lipid-enhancing agents to stabilize the tear film in patients suffering from evaporative dry eye caused by meibomian gland dysfunction.

Brand names
I-DROP PURI-DROP PUR GELI-DROP MGDI-DROP ELITE
Other names
I-DROP
02

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on I-DROP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-DROP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call